Initial insider status filed for Cue Biopharma (CUE) Chief Financial Officer

Rhea-AI Filing Summary

Cue Biopharma, Inc. reports that its Chief Financial Officer, James M. Ahlers, has become a reporting insider under SEC rules through an initial statement of beneficial ownership. The filing lists no equity transactions and no reportable holdings for Ahlers at the time of this report.

Key Figures

Buy transactions: 0 shares Sell transactions: 0 shares Holding entries: 0

3 metrics

Buy transactions 0 shares BuyShares reported in transaction summary

Sell transactions 0 shares SellShares reported in transaction summary

Holding entries 0 holdingEntries reported in transaction summary

Key Terms

Chief Financial Officer, reportingPersons, ten percent owner

3 terms

Chief Financial Officer financial

"Ahlers James M is reported with officer_title "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reportingPersons regulatory

"The reportingPersons section lists James M. Ahlers as an officer"

ten percent owner regulatory

"The is_ten_percent_owner field indicates he is not a ten percent owner"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/03/2026 - 04:17 PM Accepted by SEC EDGAR 08/03/2026 - 04:16 PM Learn about SEC filing dates

FAQ

Who is the reporting insider in Cue Biopharma (CUE)'s Form 3?

The reporting insider is James M. Ahlers, who serves as Chief Financial Officer of Cue Biopharma, Inc. This Form 3 identifies him as an officer subject to ongoing SEC insider reporting requirements.

What does this Form 3 for Cue Biopharma (CUE) disclose about transactions?

The Form 3 discloses no equity transactions by James M. Ahlers. All transaction counts, including buys, sells, and derivative exercises, are reported as zero in the transaction summary.

Does Cue Biopharma (CUE) report any holdings for James M. Ahlers in this Form 3?

The filing shows no holding entries for James M. Ahlers. The holdingEntries figure in the summary is 0, indicating no reportable securities positions in this initial statement.

What is the role of James M. Ahlers at Cue Biopharma (CUE)?

James M. Ahlers is reported as Chief Financial Officer of Cue Biopharma, Inc. His status as an officer in this role requires him to provide insider ownership reports such as this Form 3.

Are any derivative securities reported for Cue Biopharma (CUE) CFO James M. Ahlers?

No derivative securities are reported for James M. Ahlers. The derivativeSummary is empty and derivativeTransactionCount and exerciseShares are each 0 in the transaction summary.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ahlers James M

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/30/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Meluzio, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)